These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11089235)

  • 21. Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram.
    Hoy CA; Seamer LC; Schimke RT
    Cytometry; 1989 Nov; 10(6):718-25. PubMed ID: 2582962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flow cytometric fluorescence lifetime measurements.
    Crissman HA; Steinkamp JA
    Methods Cell Biol; 2001; 63():131-48. PubMed ID: 11060839
    [No Abstract]   [Full Text] [Related]  

  • 23. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P; Beardmore C; Liu LF
    Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.
    Jaks V; Jõers A; Kristjuhan A; Maimets T
    Oncogene; 2001 Mar; 20(10):1212-9. PubMed ID: 11313865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action.
    Pantazis P; Vardeman D; Mendoza J; Early J; Kozielski A; DeJesus A; Giovanella B
    Leuk Res; 1995 Jan; 19(1):43-55. PubMed ID: 7837817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benzoquinazoline derivatives as new agents affecting DNA processing.
    Marzaro G; Dalla Via L; Toninello A; Guiotto A; Chilin A
    Bioorg Med Chem; 2011 Feb; 19(3):1197-204. PubMed ID: 21216603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The stathmokinetic experiment: a single-parameter and multiparameter flow cytometric analysis.
    Traganos F; Kimmel M
    Methods Cell Biol; 1990; 33():249-70. PubMed ID: 2084471
    [No Abstract]   [Full Text] [Related]  

  • 29. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
    Del Bino G; Darzynkiewicz Z
    Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell cycle analysis of apoptosis using flow cytometry.
    Sherwood SW; Schimke RT
    Methods Cell Biol; 1995; 46():77-97. PubMed ID: 7609661
    [No Abstract]   [Full Text] [Related]  

  • 31. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
    Demarquay D; Coulomb H; Huchet M; Lesueur-Ginot L; Camara J; Lavergne O; Bigg D
    Ann N Y Acad Sci; 2000; 922():301-2. PubMed ID: 11193906
    [No Abstract]   [Full Text] [Related]  

  • 32. An improved immunocytochemical procedure for high-sensitivity detection of incorporated bromodeoxyuridine.
    Beisker W; Dolbeare F; Gray JW
    Cytometry; 1987 Mar; 8(2):235-9. PubMed ID: 3582069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydrochloric acid denaturation of colorectal tumour tissue infiltrated with bromodeoxyuridine.
    Williamson K; Gilliland R; Weir H; Grimes J; Hamilton P; Anderson N; Crockard A; Rowlands B
    Cytometry; 1994 Feb; 15(2):162-8. PubMed ID: 8168403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using monoclonal antibodies in bromodeoxyuridine-DNA analysis.
    Dolbeare F; Kuo WL; Beisker W; Vanderlaan M; Gray JW
    Methods Cell Biol; 1990; 33():207-16. PubMed ID: 1707484
    [No Abstract]   [Full Text] [Related]  

  • 36. Analysis of cell cycle by flow cytometry.
    Pozarowski P; Darzynkiewicz Z
    Methods Mol Biol; 2004; 281():301-11. PubMed ID: 15220539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis induced with different cycle-perturbing agents produces differential changes in the fluorescence lifetime of DNA-bound ethidium bromide.
    Sailer BL; Valdez JG; Steinkamp JA; Crissman HA
    Cytometry; 1998 Mar; 31(3):208-16. PubMed ID: 9515720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The future of flow cytometry.
    Wilson GD
    BJR Suppl; 1992; 24():158-62. PubMed ID: 1290692
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
    Haldane A; Holdaway KM; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1993; 32(6):463-70. PubMed ID: 8258195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of immunocytochemical detection methods of incorporated bromodeoxyuridine in hybridomas.
    Williams LS; Nordberg JA; Chau PC
    Cytometry; 1990; 11(4):490-7. PubMed ID: 2111760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.